Kyntra Bio (Nasdaq: KYNB) will release its second quarter 2026 financial results on Thursday, August 13, 2026, after market close, and will host a conference call and webcast at 5:00 PM Eastern Time to discuss results and provide a business update.
The biopharmaceutical company focuses on oncology and rare diseases, including roxadustat for anemia in chronic kidney disease and the FG-3246 antibody-drug conjugate program for metastatic castration-resistant prostate cancer, alongside its CD46-targeted PET biomarker FG-3180.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The tag-specific record included 7.31% and -1.39% 24-hour moves after prior earnings-date notices, a...
Analysis
The tag-specific record included 7.31% and -1.39% 24-hour moves after prior earnings-date notices, adding historical variability to this routine scheduling event. Recent insider activity was Neutral; reported results remain the key information to monitor.
Scheduled fourth-quarter and full-year results with a 5:00 PM ET call were announced.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Tag-specific earnings-date announcements produced mixed 24-hour reactions, ranging from -1.39% to 7.31%.
Key Terms
phase 3, phase 2, antibody-drug conjugate, pet biomarker
4 terms
phase 3medical
"development plan for the Phase 3 trial of roxadustat"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
phase 2medical
"FG-3246 ... is in Phase 2 development"
Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.
antibody-drug conjugatemedical
"a first-in-class antibody-drug conjugate (ADC) targeting CD46"
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
pet biomarkermedical
"the development of FG-3180, an associated CD46-targeted PET biomarker"
A pet biomarker is a measurable biological sign in an animal—such as a molecule in blood, an image finding, or a physiological reading—that indicates disease presence, progression, or response to treatment. Like a car’s dashboard light that signals a specific problem, these markers can make health status easier to detect and track, which matters to investors because they can enable diagnostic products, guide drug development, reduce trial time and cost, and create commercial services in veterinary and comparative medicine.
SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.
About Kyntra Bio Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
For Investor Inquiries: David DeLucia, CFA Senior Vice President and Chief Financial Officer ir@kyntrabio.com
FAQ
When will Kyntra Bio (KYNB) report its Q2 2026 financial results?
Kyntra Bio will report its Q2 2026 financial results on Thursday, August 13, 2026, after market close. According to Kyntra Bio, the release will be followed by a conference call and webcast at 5:00 PM Eastern Time the same day.
How can investors access the Kyntra Bio (KYNB) Q2 2026 earnings conference call?
Investors can access the Kyntra Bio Q2 2026 earnings call via a live audio webcast and phone. According to Kyntra Bio, participants should register online for phone dial-in details, and a webcast replay will be available on the company’s Events & Presentations webpage.
What will Kyntra Bio (KYNB) management discuss on the August 13, 2026 earnings call?
Kyntra Bio management will discuss Q2 2026 financial results and provide a business update. According to Kyntra Bio, the conference call will include a brief presentation, followed by a live Q&A session with the investment community to address additional questions about performance and strategy.
What are Kyntra Bio’s key drug programs mentioned ahead of the Q2 2026 results?
Kyntra Bio highlights roxadustat for anemia in chronic kidney disease and FG-3246 for metastatic castration-resistant prostate cancer. According to Kyntra Bio, roxadustat is approved in multiple regions, and FG-3246 is in Phase 2, supported by the CD46-targeted PET biomarker FG-3180.
Is roxadustat from Kyntra Bio (KYNB) approved, and for which indication?
Roxadustat is approved in Europe, Japan, China, and several other countries for anemia in chronic kidney disease. According to Kyntra Bio, it is indicated for CKD patients both on dialysis and not on dialysis, and a Phase 3 LR-MDS program in the U.S. is under evaluation.
What oncology program is Kyntra Bio (KYNB) advancing as of August 2026?
Kyntra Bio is advancing FG-3246 (FOR46), a first-in-class antibody-drug conjugate targeting CD46, in Phase 2 for metastatic castration-resistant prostate cancer. According to Kyntra Bio, this program includes development of the associated CD46-targeted PET biomarker FG-3180 to support patient selection and monitoring.
